On this thanksgiving day, Whosleftholdindabag, the Self Proclaimed Charity Investor, spending his charity day
supporting the well know NWBO paid basher LC2020......
Dude you have set a very high standards for yourself!!! LOL
KAMA looking you in the EYE!!!!
Its time for a bigger bag for whoslefthHOLDINGdaBG...... Bag holder!! go to it now!!
Is it so hard to embrace the future? NVCR is sinking and you know it.
Here is the future.
Or they know something we already know.
Here comes the sub 10s.
Here comes the sub 10s.
Optune has a dire future. The tail-spin mode of the sp will continue and it is going to get worse in the next few weeks. You are still advocating it. No offense the two boards you are moderating have pretty bad record in terms of sp.
800 GBM patients have received DCVax-L and the increase over the last three months is 200. Those patients have to pay everything out of their own pockets. If they were not convinced by provable records on the efficacy of DCVax-L, would they try DCVax-L?
Have you read my DD which clearly indicates that DCVax-L is on the radar of the Moonshot program? There is no chance Optune is going to win. Do the right thing and tell the investors the truth.
Present away - This wearable thing is very costly hope as it Lacks effectiveness IMO.... And now everyone is very aware of that IMO...
That's why SP has been dropping continuously from a high of about $82 in early June to $16 last Friday!!
The cat is out of the hat...
Also at SITC
Abstract Number 581: Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
Abstract Number 607: TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study.
Abstract Number 1080: Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages.
It is really the time to reconsider your investment in NVCR. It is so simple: Download the paper and consult several best experts on immunotherapy to seek their opinions.
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients
This person, whosleftholdindabag, is most likely a NWBO basher and a Pretend NVCR Investor IMO..
His posting history shows only 18 Posts on NVCR MB, WHILE having posted 820 on NWBO MB...
And that history support why he might be connected to EX..
It seems like he is not playing the game with his own money. As he repeatedly claimed, all the proceeds from the investment will go to charity. What will happen if there are no proceeds?
Can any longs in NWBO give credit to anyone who liked EX's posts? Absolutely not. In fact, he and EX are on the same league.
Just a bigger bag holder lol
Some got 18
LOL - Published, 'OS 13,2 months vs OS 9.9 months Yes. But is it worth the Trouble, Cost, & Hope??
"Overall survival was significantly longer with TTFields therapy and standard therapy than with standard therapy alone (median 13·2 months [95% CI 10·3–15·5] vs 9·9 months [8·1–11·5]
How could you post it so late? Did I mention months ago that it smells fishy since each member of NVCR C-Suite started selling after May 28 2018 on which the first results of DCVax-L p3 trial results were published? Do you remember what you said back then? You should resign from this board as a moderator.
INNOVATE-3 fails. According to its final data analysis, the patients treated with TTFields plus paclitaxel had a mOS of 12.2 months compared to 11.9 months mOS in the paclitaxel-only arm https://www.businesswire.com/news/home/20230828160039/en/Novocure-Provides-Update-on-Phase-3-ENGOT-ov50-GOG-3029-INNOVATE-3-Trial-Evaluating-Tumor-Treating-Fields-Therapy-in-Platinum-resistant-Ovarian-Cancer/
Busted - An NVCR Cancer Charity Investor. Who Hates Other Cancer Therapy Companies, Who Is Admittedly a Gambler...
What a complete package of Disappointment..
Andres Salazar owns a family business which has the patent of poly-iclc, an essential ingredient for maximizing the efficacy of DCVax-L.
Here is the ongoing clinical trial which has Oncovir has one of the collaborators along with Merck.
Check the newly hired employees of Oncovir. They are high-caliber professionals and they don't join a company which has no future. Keep in mind that Oncovir was involved in over 70 clinical trials and none of them were successful. Its old patent of poly-iclc expired in July. But he filed for new patents already. Would you file a new patent and hire new employees if your product in the past 20 years didn't deliver not a single success?
You had this statement in one of your posts on NWBO board...
"All we need to know is if Andres Salazar is all-in poly-iclc, if he is, we just need to plan all-in too. If we cannot all in, at least, we can double, triple, or quadruple our current position. It is that simple!"
What do you mean by that & who is Andres Salazar??
IMO Dude is not a Charity Investor for Cancer, OTHERWISE he would invest unbiasedly to all potential new therapies...
This dude is Pumping NVCR & Bashing NWBO!! A Charitable human would never ever be So Selectively Revengeful!!
Dude hiding behind a great cause for whatever reason IMO...
He probably thinks thermo shorts his beloved NVCR. He should first question the integrity of the whole NVCR management team.